Skip to main content
SpringerLink
Log in

Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study

  • Research Letter
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Liu J, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, et al. Inhibition of T cell signaling by immunophilin–ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry. 1992;31(16):3896–901.

    Article  CAS  PubMed  Google Scholar 

  2. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant. 2009;43(8):643–53.

    Article  CAS  PubMed  Google Scholar 

  3. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307.

    Article  CAS  PubMed  Google Scholar 

  4. Bruckmueller H, Cascorbi I. Drug–drug–gene interactions: a call for clinical consideration. Clin Pharmacol Ther. 2021;110(3):549–51.

    Article  PubMed  Google Scholar 

  5. Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102(1):45–51.

    Article  CAS  PubMed  Google Scholar 

  6. Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet. 2020;59(11):1357–92.

    Article  CAS  PubMed  Google Scholar 

  7. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole—a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;1(Suppl 1):2–9.

    Article  Google Scholar 

  8. Chu S, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol. 1993;33(8):719–26.

    Article  CAS  PubMed  Google Scholar 

  9. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541–51.

    Article  CAS  PubMed  Google Scholar 

  10. Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, et al. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol. 2013;69(3):439–48.

    Article  CAS  PubMed  Google Scholar 

  11. Mori T, Kato J, Yamane A, Sakurai M, Kohashi S, Kikuchi T, et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95(5):564–9.

    Article  CAS  PubMed  Google Scholar 

  12. Imamura CK, Furihata K, Okamoto S, Tanigawara Y. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol. 2016;56(4):408–13.

    Article  CAS  PubMed  Google Scholar 

  13. Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, et al. Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet. 2016;55(12):1535–45.

    Article  CAS  PubMed  Google Scholar 

  14. Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos. 2010;38(2):241–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Miyata Y, Akamatsu N, Sugawara Y, Kaneko J, Yamamoto T, Suzuki H, et al. Pharmacokinetics of a once-daily dose of tacrolimus early after liver transplantation: with special reference to CYP3A5 and ABCB1 Single nucleotide polymorphisms. Ann Transplant. 2016;21:491–9.

    Article  CAS  PubMed  Google Scholar 

  16. Koristkova B, Grundmann M, Kacirova I, Urinovska R. Drug interaction between clarithromycin and tacrolimus—a case report. Clin Ther. 2017;39(8):e86–7.

    Google Scholar 

  17. Cheung KK, Senior PA. Tacrolimus toxicity in islet transplantation due to interaction with macrolides. Clin Diabetes Endocrinol. 2016;26(2):2.

    Article  Google Scholar 

Download references

Acknowledgments

We would like to thank Editage for editing and reviewing the manuscript in the English language.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

    Toshinori Hirai & Takuya Iwamoto

  2. Department of Hematology and Oncology, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

    Kazuko Ino & Isao Tawara

  3. Department of Clinical Laboratory, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

    Makoto Ikejiri

Authors
  1. Toshinori Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuko Ino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Ikejiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isao Tawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuya Iwamoto.

Ethics declarations

Funding

Not applicable.

Conflict of interest

Not applicable.

Ethics approval

This case series was deemed exempt from the institutional review board.

Consent to participate

Written informed consent was obtained from each patient to participate in this study.

Consent for publication

Written informed consent was obtained from each patient to publish as research letter.

Availability of data and material

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available owing to ethical restrictions.

Code availability

Not applicable.

Authors’ contributions

T.H. and T.I. contributed to the study conception and design. Material preparation, data collection, and analysis were performed by T. H, K.I., and M.I. The first draft of the manuscript was written by T.H., I.T., and T.I., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 439 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hirai, T., Ino, K., Ikejiri, M. et al. Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study. Eur J Drug Metab Pharmacokinet 47, 889–893 (2022). https://doi.org/10.1007/s13318-022-00790-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-022-00790-9

Search

Navigation